Lanadelumab
Takhzyro (lanadelumab) is an antibody pharmaceutical. Lanadelumab was first approved as Takhzyro on 2018-08-23. It has been approved in Europe to treat hereditary angioedemas. The pharmaceutical is active against plasma kallikrein.
| Trade Name | Takhzyro |
|---|---|
| Common Name | Lanadelumab |
| Indication | hereditary angioedemas |
| Drug Class | Monoclonal antibodies: fully human, immunomodulating |
